Cereno Scientific’s CEO on novel therapies for rare diseases

(9:54)

Cereno Scientific's Capital Markets Day 2024

(2:47:6)

Cereno Scientific presents positive topline results of Phase IIa trial with CS1 in PAH

(1:15:10)

Cereno Scientific - Corporate presentation

(3:25)

Cereno Scientific – executive interview (28 November 2024)

(26:15)

Cereno Scientific leaps towards phase II readout with CS1

(13:34)

Cereno Scientific at ESC 2024

(3:8)

BioStock | Cereno - patient case study data | June 2023

(9:21)

Cereno Scientific | BioStock Life Science Summit 2024

(15:4)

What will Cereno Scientifics 250 MSEK loan mean for the shareholders?

(8:12)

Cereno at ESC 2023: Our CEO speaks about the latest updates in our Phase II study of CS1 in PAH.

(2:50)

BioStock Life Science Summit 2021 | Cereno Scientific

(16:23)

Insights Series S2E1: Prof. Benza on remarkable patient case study data from Phase II study of CS1

(4:42)

Cereno Scientific – executive interview (7 October 2024)

(29:52)

BioStock Life Science Spring Summit 2022 | Cereno Scientific

(20:52)

Cereno Scientific brings novel cardiovascular disease candidate to the clinic

(13:12)

LSX Nordic Congress 2019 Presentations - Cereno Scientific

(20:35)

Ice Camping, Chicken, Football \u0026 BIG FISH! (insulated shanty)

(31:6)

BioGaia ProBiotics Review - Do they really work?

(10:12)

Bloomberg Turnaround: AstraZeneca

(24:7)

Dr. Michael Holinstat presents new preclinical data for CS585 at ESC Congress 2024

(6:35)

Life Sciencedagen 2024

(27:34)